Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Characteristics of patients with GPA and healthy controls

From: Regulatory and effector B cell cytokine production in patients with relapsing granulomatosis with polyangiitis

  HC GPA, no future relapse GPA, future relapse
Subjects, n (% male) 13 (46) 13 (46) 13 (46)
Age, years, mean (range) 55 (44–74) 52 (32–76) 52 (32–75)
PR3-ANCA titer, median (range)   1:40 (0 to >640) 1:80 (20 to >640)
Disease duration, years, median (range)   12.6 (5.5–31.5) 15.3 (2.3–24.3)
Number of previous relapses, median (range)   2 (0–5) 5 (1–10)
Time to relapse after sample, days, median (range)   n/a 74 (14–157)
Disease form, n (%)    
 Localized   0 (0) 0 (0)
 Early systemic   2 (15.4) 2 (15.4)
 Generalized   8 (61.5) 9 (69.2)
 Severe   3 (23.1) 2 (15.4)
Treatment at time of sampling, n (%)    
 Aza   1 (7.7) 3 (23.1)
 Pred   1 (7.7) 1 (7.7)
 MMF + pred   2 (15.4) 3 (23.1)
 No immunosuppressive therapy   9 (69.2) 6 (46.2)
B cell phenotype in %, median (range)    
 Total CD19+ B cells 12.3 (6.6–22.24) 9.8 (6.3–28.6) 9.9 (3.4–19.9)
 Transitional B cells 10.77 (3.9–17.6) 9.2 (4.8–18.1) 9.3 (3.1–11.7)
 Naive B cells 63.6 (37.4–83.4) 79.0 (74.5–90.1) 79.3 (60.1–85.7)
 Memory B cells 22.4 (6.6–54.0) 8.1 (4.2–29.7) 8.2 (2.3–19.5)
 CD24highCD38high B cells 6.6 (2.2–9.6) 4.6 (2.1–11.8) 5.3 (0.9–8.5)
 CD24highCD27+ B cells 15.5 (3.5–45.4) 3.3 (2.1–24.8) 3.4 (0.7–10.8)
 CD5+ B cells 23.4 (12.1–57.6) 19.8 (12.1–64.2) 18.9 (4.7–49.9)
  1. ANCA anti-neutrophil cytoplasmic antibody, Aza azathioprine, GPA granulomatosis with polyangiitis, HC healthy controls, MMF mycophenolate mofetil, n/a not applicable, PR3 proteinase-3, Pred prednisolone